Detailed results from clinical feasibility studies show immediate improvement in blood pressure stability and durable reduction of hypotensive symptoms, resulting in improved quality of life Most people living with spinal cord injury experience blood pressure instability, which represents a key unmet needToday’s concurrent publications provide clinical evidence for ARC-IM® Therapy ahead of the Company’s planned initiation of the Empower BP global pivotal trial later this year EINDHOVEN, The Netherlands, Sep ...

产品发布与技术创新 - 公司正式推出全球首款骨密度匹配前路腰椎椎间融合装置DEXA-L™ 该产品属于专利DEXA™技术平台系列 是首批植入手术使用的创新产品[1] - DEXA-L™是全球首个用于前路腰椎椎间融合术(ALIF)的独立装置 采用仿骨结构技术 能够根据患者骨密度和质量进行个性化匹配[2] - 该技术平台扩展了腰椎融合术的适应症 使骨质量较差的患者也能接受治疗 内部测试显示可减少沉降现象[3] 临床价值与市场潜力 - 美国首例手术由加州圣地亚哥的Daniel Barba医生完成 医生强调该技术可实现植入物模量与患者骨密度的精准匹配 突破传统"一刀切"模式[3] - 根据CDC数据 美国50岁以上人口中近半数存在骨量低下问题 对应数百万需要匹配骨密度植入物的脊柱手术患者群体[3] - 该装置能同时治疗骨质疏松症、骨量减少患者及需要手术的正常骨密度患者 填补了骨密度不匹配领域的临床需求空白[3] 公司战略与技术积累 - DEXA技术平台建立在颈椎融合植入物DEXA-C™的成功基础上 后者已在美国多家医疗机构应用[3] - 公司专注于通过专有微创和再生技术为脊柱植入市场提供新解决方案 致力于通过创新和以患者为中心的设计改善手术效果[4] - 该产品发布标志着公司在脊柱手术领域的又一个里程碑式进展 同时满足标准患者和具有挑战性的复杂病例需求[3]

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 17, 2025 /PRNewswire/ -- Berger Montague PC, a nationally recognized securities litigation law firm, is investigating potential securities law violations involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). A class action lawsuit was recently filed on behalf of investors who acquired RxSight securities between May 7, 2024 and July 8, 2025 (the "Class Period"). Caitlin AdorniBerger Montague(267) 764-4865[email protected] SOURCE Berg ...

Private equity firms Blackstone and TPG revived their interest in acquiring medical device maker Hologic , a person close to the transaction said on Wednesday. ...

Key TakeawaysThe Federal Reserve enacted a widely anticipated 25-basis-point rate cut, bringing the federal funds rate to a range of 4%-4.25%. Markets showed a mixed reaction, with the S&P 500 dipping slightly and the dollar strengthening. The Fed signaled two more cuts are likely this year.Apple (AAPL) is reportedly testing foldable iPhones in Taiwan, aiming for a 10% boost in total phone shipments in 2026, with a preliminary target of producing around 95 million units. The company expects the foldable mod ...

Varex Imaging (NasdaqGS:VREX) Conference September 17, 2025 03:15 PM ET Company ParticipantsShubham Maheshwari - CFONoneHi, good afternoon, and welcome to the Snowden & Company September Small Cap Investor Conference. The next company to present is Varex Imaging. We have with us the CFO, Sam Maheshwari, and the Director of Investor Relations, Chris Belfiore. This session will be a fireside chat. It'll last about 30 minutes. I have a list of questions I'll go through, but there might be some time at the end ...

SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase in the Company’s share repurchase program. The share repurchase program now totals $2 billion. “We are pleased to announce that our Board of Directors has authorized an increase to our share repurchase program,” said Al White, President and Chief Executive Officer. “This decision underscores the strength of our ...

Hologic (NASDAQ:HOLX) soared 7.6% after a report that Blackstone Inc. (BX) and TPG (TPG) have renewed their interest in a takeover of the medical device maker. The investment companies have restarted talks with Hologic's board in recent weeks about a ...

CorMedix Inc. (NASDAQ:CRMD) is one of the best affordable biotech stocks to invest in now. On September 9, Citizens JMP analyst Jason Butler reiterated a Buy rating on CorMedix Inc. (NASDAQ:CRMD) and set a price target of $22.00. Is CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? In other news, CorMedix Inc. (NASDAQ:CRMD) announced on September 2 the successful completion of its previously announced acquisition of Melinta Therapeutics LLC. Melinta Therapeutics LLC is a pri ...

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between May 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”, of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO D ...